Library / Blends / Semaglutide + Tesamorelin
GLP-1 + visceral-fat GHRH analog
Semaglutide + Tesamorelin
Blend
ClassTwo-agent metabolic stack
Typical routes in papersWeekly GLP-1 + daily tesamorelin in descriptions
Half-life contextSema ~1 week; tesamorelin minutes
EvidenceEach labeled or trial-backed alone; combo is clinic/off-label talk
What it is
A two-schedule stack, rarely a true single vial: weekly semaglutide for appetite/glucose, daily tesamorelin for the visceral-fat GH-axis story. Different clocks, different pens.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- What people want: eat less and specifically work deep belly fat.
- Muscle and protein intake need attention when a GLP-1 is in play.
- Research cakes that freeze them together ignore the different half-lives.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Sema: GLP-1 RA. Tesamorelin: GHRH analog with a visceral-fat label as Egrifta.
Possible side effects / caveats
GI plus glucose/IGF shifts. Two prescriptions in the approved world, not one mystery mix.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Typical talk | Weekly sema titration + tesamorelin 2 mg label logic | Separate products | See solo pages |
| See also | Semaglutide, Tesamorelin | Parts |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.